Live Attenuated H7N7 Influenza Vaccine Primes for a Vigorous Antibody Response to Inactivated H7N7 Influenza Vaccine
This article, published in Vaccine, reports on a study to evaluate the safety and immunogenicity of two candidate H7 pandemic live attenuated influenza vaccines (pLAIVs) and their ability to prime for responses to an unadjuvanted H7 pandemic inactivated influenza vaccine. The authors found that pLAIV priming established long-term immune memory that was cross-reactive with other H7 influenza strains. Understanding the mechanisms underlying this priming may aid in pandemic vaccine development. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Babu TM, Levine M, Fitzgerald T, et al.
» Visit web page (English)
(Located at www.sciencedirect.com)
Citation: Babu TM, Levine M, Fitzgerald T, et al. Live Attenuated H7N7 Influenza Vaccine Primes for a Vigorous Antibody Response to Inactivated H7N7 Influenza Vaccine. Vaccine. 2014;32(50):6798-6804.
Resource types: Peer-reviewed journal